U.S. Clinical Laboratory Services Market Size, Share, Growth Opportunities, Trends, and Analysis 2034
U.S. Clinical Laboratory Services Market Size, Share, Growth Opportunities, Trends, and Analysis 2034
Clinical laboratories analyze patient specimens to provide information that helps healthcare professionals assess medical conditions and determine appropriate treatment strategies. The growing emphasis on preventive healthcare, regular health check-ups, and timely disease detection is increasing the importance of laboratory testing in the U.S. healthcare system. In addition, advancements in laboratory automation and diagnostic technologies are encouraging service providers to improve operational efficiency and testing capabilities.
According to Fortune Business Insights, the U.S. clinical laboratory services market size was worth USD 101.73 billion in 2023 and is projected to grow at a CAGR of 7.3% during the forecast period from 2024 to 2032. The market is supported by increasing healthcare expenditure, rising demand for routine diagnostic tests, and the growing prevalence of chronic and infectious diseases across the country. Clinical laboratory services play an essential role in identifying health conditions, supporting treatment decisions, monitoring disease progression, and promoting early diagnosis.
The U.S. clinical laboratory services market features established laboratory networks and specialized diagnostic service providers. Companies compete by expanding their testing portfolios, strengthening laboratory capabilities, improving service accessibility, and introducing advanced diagnostic solutions. Key companies identified by Fortune Business Insights include:
Laboratory Corporation of America (U.S.)
Quest Diagnostics Incorporated (U.S.)
Illumina, Inc. (U.S.)
Eurofins Scientific (Luxembourg)
UNILABS (A.P. Moller Holding A/S) (Switzerland)
NeoGenomics Laboratories, Inc. (U.S.)
ARUP Laboratories (U.S.)
Sonic Healthcare Limited (Australia)
Laboratory Corporation of America, Quest Diagnostics Incorporated, and Eurofins Scientific held prominent positions in the market in 2022, supported by their service portfolios and established presence. Strategic partnerships, acquisitions, and laboratory expansion initiatives remain important approaches for strengthening competitive positions and broadening access to diagnostic services.
Market Drivers
Growing prevalence of chronic diseases: Increasing cases of chronic and infectious conditions are generating demand for diagnostic testing. Laboratory services support the identification and monitoring of conditions such as diabetes, cardiovascular diseases, cancer, and other long-term disorders.
Increasing focus on early diagnosis: Greater awareness of preventive healthcare and routine health examinations encourages patients and healthcare professionals to use laboratory testing for identifying potential health problems earlier.
Healthcare expenditure and reimbursement support: Healthcare spending and public and private reimbursement arrangements support the adoption of clinical laboratory services across different patient groups.
Advancements in laboratory automation: Automated equipment, laboratory workflow systems, and digital integration can improve operational processes and support the delivery of diagnostic services.
Market Restraints
Pricing pressure is a major factor that may limit market expansion. Discounting and pressure on diagnostic test prices can affect laboratory service providers' financial performance. The cost of healthcare testing may also influence patients' decisions to seek care, potentially resulting in delayed procedures and prescriptions. Managing service costs while maintaining reliable testing and operational quality remains an important consideration for market participants.
Competition in the U.S. clinical laboratory services market is influenced by service breadth, diagnostic capabilities, operational efficiency, and the ability to respond to changing healthcare requirements. Major providers are strengthening their positions through partnerships, acquisitions, technology integration, and the expansion of laboratory operations.
Fortune Business Insights highlights several industry developments. In March 2023, Illumina, Inc. and Myriad Genetics, Inc. expanded their strategic partnership to broaden access to oncology homologous recombination deficiency testing in the U.S. In July 2022, Laboratory Corporation of America began offering testing for monkeypox using the U.S. Centers for Disease Control and Prevention's orthopoxvirus test. In May 2022, the company announced the acquisition of diagnostic clinical laboratory services from AtlantiCare in Southern New Jersey.
These developments illustrate how partnerships, specialized testing, and acquisitions can help companies expand service availability and strengthen their positions in the competitive landscape.
By Test Type (Clinical Chemistry, Hematology, Genetic Testing, Microbiology & Cytology, and Others)
By Age (Pediatric and Adult)
By Source of Payment (Public, Private, and Out of Pocket), and
By Service Provider (Hospital-based Laboratories, Stand-alone Laboratories, Clinic-based Laboratories, and Others)
Explore the full research report with detailed insights and TOC: https://www.fortunebusinessinsights.com/u-s-clinical-laboratory-services-market-107909
This report focuses specifically on the United States rather than comparing individual global regions. Market demand across the country is influenced by healthcare expenditure, the prevalence of chronic and infectious diseases, demand for routine health examinations, reimbursement support, and the availability of diagnostic services.
The report also identifies the importance of laboratory access and service delivery in supporting patient care. Hospital-based, stand-alone, and clinic-based laboratories contribute to the national testing landscape through different healthcare settings. Continued development of diagnostic capabilities and laboratory networks is relevant to the market's growth outlook.
Laboratory automation and workflow integration may help providers improve efficiency and manage growing testing requirements. Genetic testing and other specialized diagnostic services are also important areas within the market's test-type segmentation. Meanwhile, partnerships and acquisitions can help companies broaden their capabilities and extend access to laboratory services.
However, pricing pressure remains a challenge for service providers. Balancing affordability with efficient operations and dependable testing will be important as the market develops. Overall, demand for diagnostic services, greater awareness of early detection, and advances in laboratory operations are key factors shaping the future of the U.S. clinical laboratory services market.
What Everyone Should Know About Japan’s Market -U.S. Clinical Laboratory Services Market- Insights